Determination of SK3497 in Rat Plasma and Its Application in a Pharmacokinetic Study of SK3497

 

 Buy Article Permissions and Reprints

Abstract

In this study, a sensitive and reliable method for the quantitation of SK3497 in rat plasma was developed and validated using high performance liquid chromatography. The plasma samples were prepared by deproteinization, and sildenafil was used as an internal standard. Chromatographic separation was achieved using a reversed-phase (C18) column. The mobile phase, 0.02 M ammonium acetate buffer:acetonitrile (45:55, v/v), was run at a flow rate of 1.0 mL/min, and the column eluent was monitored using an ultraviolet detector at 254 nm at room temperature. The retention times of sildenafil (an internal standard), and SK3497 were approximately 5.6 and 8.3 min, respectively. The detection limit of SK3497 in rat plasma was 0.03 μg/mL. Pharmacokinetic parameters of SK3497 was evaluated after intravenous (i. v.; at doses of 15 mg/kg) and oral (p.o.; at doses of 30 mg/kg) administration of SK3497 in rats. After p.o. administration (30 mg/kg) of SK3497, F-value was approximately 53.0%. The protein binding of SK3497 to 4% human serum albumin were also described.

• References

• 1 Yoo HH, Kim NS, Im GJ et al. Pharmacokinetics and tissue distribution of a novel PDE5 inhibitor, SK-3530, in rats. Acta Pharmacol Sin 2007; 28: 1247-1253
  CrossrefPubMedGoogle Scholar
• 2 Hatzimouratidis K, Hatzichristou DG. Looking to the future for erectile dysfunction therapies. Drugs 2008; 68: 231-250
  CrossrefPubMedGoogle Scholar
• 3 Lincoln TM. CyClic GMP and phosphodiesterase 5 inhibitor therapies: what’s on the horizon. Mol Pharmacol 2004; 66: 776-784
  PubMedGoogle Scholar
• 4 Aversa A, Bruzziches R, Pili M et al. Phosphodiesterase 5 inhibitors in the treatment of erectile dysfunction. Curr Pharm Res 2006; 12: 3467-3484
  CrossrefPubMedGoogle Scholar
• 5 Broderick GA. P.o. pharmacotherapy and the contemporary evaluation and management of erectile dysfunction. Rev Urol 2003; 5: S9-S20
  PubMedGoogle Scholar
• 6 http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070107.pdf
  PubMed
• 7 Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharm Res 1993; 10: 1009-1095
  CrossrefPubMedGoogle Scholar